5th RNAi-Based Therapeutics Summit
Despite exciting advancements and new investments into the field, the development of new RNAi therapeutics is plagued by difficulties with extra-hepatic delivery and scale-up of manufacturing production. These hurdles are a stark reminder that we need experts from all corners of the industry to join forces and pioneer the way forward.
The 5th RNAi-Based Therapeutics Summit returns to Boston this February with brand-new content and a refreshed pre-conference workshop day showcasing novel platforms and strategies for targeting beyond the liver.
This industry dedicated meeting will unite 100+ technical and strategic leaders including Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Transcode Therapeutics, Sirnaomics and OliX Pharmaceuticals to face key bottlenecks within the field through data-driven presentations and interactive, discussion-led sessions to accelerate RNAi therapeutics into the clinic and towards approval.
